It was reported that oral RTB101, an mTOR inhibitor, increased interferon-induced antiviral gene expression and reduced laboratory-confirmed respiratory tract infections (RTIs) compared to placebo in adults over 65 years (49). Here, MTOR is linked to Respiratory tract infection.